

# João M Frazão

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6262846/publications.pdf>

Version: 2024-02-01

57  
papers

2,976  
citations

331259

21  
h-index

182168

51  
g-index

57  
all docs

57  
docs citations

57  
times ranked

2829  
citing authors

#	ARTICLE	IF	CITATIONS
1	Could Bone Biomarkers Predict Bone Turnover after Kidney Transplantation?â€”A Proof-of-Concept Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 457.	1.0	2
2	Efficacy and safety of calcium carbonate in normophosphataemic patients with chronic kidney disease Stages 3 and 4. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 550-555.	1.4	6
3	Management of RAASi-associated hyperkalemia in patients with cardiovascular disease. <i>Heart Failure Reviews</i> , 2021, 26, 891-896.	1.7	17
4	Sclerostin and DKK1 circulating levels associate with low bone turnover in patients with chronic kidney disease Stages 3 and 4. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2401-2408.	1.4	21
5	Improvements in six aspects of quality of care of incident hemodialysis patients â€” a real-world experience. <i>BMC Nephrology</i> , 2021, 22, 333.	0.8	0
6	Low bone turnover is associated with plain X-ray vascular calcification in predialysis patients. <i>PLoS ONE</i> , 2021, 16, e0258284.	1.1	7
7	Influence of gender and age on haemodialysis practices: a European multicentre analysis. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 217-224.	1.4	12
8	Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review. <i>Revista Portuguesa De Cardiologia</i> , 2020, 39, 517-541.	0.2	8
9	P1514 PERIPHERAL VASCULAR DISEASE IN DIABETIC PATIENTS ON HEMODIALYSIS - RISK OF HOSPITALIZATION AND MORTALITY IN A LARGE EUROPEAN COHORT. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
10	The bone-vessel axis in chronic kidney disease: An update on biochemical players and its future role in laboratory medicine. <i>Clinica Chimica Acta</i> , 2020, 508, 221-227.	0.5	18
11	The Role of the Old and the New Calcimimetic Agents in Chronic Kidney Disease-Mineral and Bone Disorder. , 2020, , 155-173.		0
12	Evaluation of Renal Osteodystrophy and Serum Bone-Related Biomarkers in a Peritoneal Dialysis Population. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1689-1699.	3.1	6
13	Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. <i>Kidney International</i> , 2019, 95, 1064-1078.	2.6	33
14	Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 269-280.	1.4	29
15	Achievement of renal anemia KDIGO targets by two different clinical strategies â€” a European hemodialysis multicenter analysis. <i>BMC Nephrology</i> , 2019, 20, 5.	0.8	7
16	Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 80-88.	1.4	32
17	Does Impedance Matter When Recording Spikes With Polytrodes?. <i>Frontiers in Neuroscience</i> , 2018, 12, 715.	1.4	74
18	Parathyroidectomy in Persistent Post-transplantation Hyperparathyroidism â€” Single-center Experience. <i>Transplantation Proceedings</i> , 2017, 49, 795-798.	0.3	13

#	ARTICLE	IF	CITATIONS
19	Dietary magnesium supplementation prevents and reverses vascular and soft tissue calcifications in uremic rats. <i>Kidney International</i> , 2017, 92, 1084-1099.	2.6	85
20	Cortical bone analysis in a predialysis population: a comparison with a dialysis population. <i>Journal of Bone and Mineral Metabolism</i> , 2017, 35, 513-521.	1.3	21
21	Higher mineralized bone volume is associated with a lower plain X-Ray vascular calcification score in hemodialysis patients. <i>PLoS ONE</i> , 2017, 12, e0179868.	1.1	11
22	Validating silicon polytrodes with paired juxtacellular recordings: method and dataset. <i>Journal of Neurophysiology</i> , 2016, 116, 892-903.	0.9	81
23	Evolution of bone disease after kidney transplantation: A prospective histomorphometric analysis of trabecular and cortical bone. <i>Nephrology</i> , 2016, 21, 55-61.	0.7	15
24	The role of bone biopsy for the diagnosis of renal osteodystrophy: a short overview and future perspectives. <i>Journal of Nephrology</i> , 2016, 29, 617-626.	0.9	16
25	Bonsai: an event-based framework for processing and controlling data streams. <i>Frontiers in Neuroinformatics</i> , 2015, 9, 7.	1.3	389
26	Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet). <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 567-571.	1.4	12
27	FP416PHOSPHATE RESTRICTION PRESERVES BONE VOLUME IN EARLY AND LATE STAGES OF CKD IN RATS. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii209-iii209.	0.4	0
28	Calciphylaxis: from the disease to the diseased. <i>Journal of Nephrology</i> , 2015, 28, 531-540.	0.9	21
29	Nutrition and dietary intake and their association with mortality and hospitalisation in adults with chronic kidney disease treated with haemodialysis: protocol for DIET-HD, a prospective multinational cohort study. <i>BMJ Open</i> , 2015, 5, e006897-e006897.	0.8	24
30	The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder. <i>Nefrologia</i> , 2013, 33, 835-44.	0.2	7
31	Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2012, 367, 2482-2494.	13.9	805
32	Non-Calcium-Containing Phosphate Binders: Comparing Efficacy, Safety, and Other Clinical Effects. <i>Nephron Clinical Practice</i> , 2012, 120, c108-c119.	2.3	22
33	Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism?. <i>BMC Nephrology</i> , 2012, 13, 76.	0.8	9
34	Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity. <i>Clinical Nephrology</i> , 2011, 76, 233-243.	0.4	19
35	Femoral bone mineral density reflects histologically determined cortical bone volume in hemodialysis patients. <i>Osteoporosis International</i> , 2010, 21, 619-625.	1.3	18
36	Impact of Vitamin D Dose on Biochemical Parameters in Patients with Secondary Hyperparathyroidism Receiving Cinacalcet. <i>Nephron Clinical Practice</i> , 2009, 112, c41-c50.	2.3	7

#	ARTICLE	IF	CITATIONS
37	Low Bone Volume—A Risk Factor for Coronary Calcifications in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 450-455.	2.2	95
38	Adynamic bone disease: clinical and therapeutic implications. <i>Current Opinion in Nephrology and Hypertension</i> , 2009, 18, 303-307.	1.0	43
39	Biosimilars and biopharmaceuticals: what the nephrologists need to know—a position paper by the ERA-EDTA Council. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3731-3737.	0.4	62
40	Effects of Sevelamer Hydrochloride and Calcium Carbonate on Renal Osteodystrophy in Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 405-412.	3.0	153
41	The OPTIMA Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 36-45.	2.2	202
42	Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data. <i>Kidney International</i> , 2008, 74, S38-S43.	2.6	16
43	Secondary Hyperparathyroidism Disease Stabilization Following Calcimimetic Therapy. <i>CKJ: Clinical Kidney Journal</i> , 2008, 1, i12-i17.	1.4	4
44	Cardiovascular risk in dialysis patients: an X-ray vision on vascular calcifications. <i>Kidney International</i> , 2008, 74, 1505-1507.	2.6	6
45	Evaluation of parathyroid gland angiogenesis in chronic kidney disease associated with secondary hyperparathyroidism. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2889-2894.	0.4	8
46	A search and rescue robot with teleoperated tether docking system. <i>Industrial Robot</i> , 2007, 34, 332-338.	1.2	20
47	RAPOSA: Semi-Autonomous Robot for Rescue Operations. , 2006, , .		27
48	Calcimimetic agents: Review and perspectives. <i>Kidney International</i> , 2003, 63, S91-S96.	2.6	37
49	The calcimimetic agents: Perspectives for treatment. <i>Kidney International</i> , 2002, 61, S149-S154.	2.6	22
50	A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. <i>Kidney International</i> , 2000, 58, 436-445.	2.6	162
51	Intermittent doxercaliferol (1 $\alpha$ -Hydroxyvitamin D2) therapy for secondary hyperparathyroidism. <i>American Journal of Kidney Diseases</i> , 2000, 36, 550-561.	2.1	118
52	Calcium-sensing receptor and calcimimetic agents. <i>Kidney International</i> , 1999, 56, S52-S58.	2.6	36
53	Hypokinetic azotemic osteodystrophy. <i>Kidney International</i> , 1998, 54, 1000-1016.	2.6	48
54	Intermittent oral 1 $\alpha$ -hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 68-72.	0.4	46

#	ARTICLE	IF	CITATIONS
55	Epstein-Barr-virus-induced interstitial nephritis in an HIV-positive patient with progressive renal failure. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 1849-1852.	0.4	12
56	Calcitriol in the Management of Renal Osteodystrophy. <i>Seminars in Dialysis</i> , 1996, 9, 316-325.	0.7	12
57	Symptomatic hypercalcemia in a diabetic patient undergoing continuous ambulatory peritoneal dialysis: Value of bone biopsy in the diagnosis and management. <i>American Journal of Kidney Diseases</i> , 1995, 26, 831-835.	2.1	0